MX2024005508A - Peptidos novedosos. - Google Patents

Peptidos novedosos.

Info

Publication number
MX2024005508A
MX2024005508A MX2024005508A MX2024005508A MX2024005508A MX 2024005508 A MX2024005508 A MX 2024005508A MX 2024005508 A MX2024005508 A MX 2024005508A MX 2024005508 A MX2024005508 A MX 2024005508A MX 2024005508 A MX2024005508 A MX 2024005508A
Authority
MX
Mexico
Prior art keywords
novel peptides
cancers
cea
antibodies
treatment
Prior art date
Application number
MX2024005508A
Other languages
English (en)
Spanish (es)
Inventor
Peter Ellmark
Schantz Laura Von
Anna Säll
Laura Varas
Mattias Levin
Karin Hägerbrand
Original Assignee
Alligator Bioscience Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2204539.7A external-priority patent/GB202204539D0/en
Priority claimed from GBGB2212801.1A external-priority patent/GB202212801D0/en
Application filed by Alligator Bioscience Ab filed Critical Alligator Bioscience Ab
Publication of MX2024005508A publication Critical patent/MX2024005508A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2024005508A 2021-11-05 2022-11-04 Peptidos novedosos. MX2024005508A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB202115925 2021-11-05
GBGB2204539.7A GB202204539D0 (en) 2022-03-30 2022-03-30 Novel peptides
GBGB2212801.1A GB202212801D0 (en) 2022-09-02 2022-09-02 Novel peptides
PCT/EP2022/080861 WO2023079102A2 (en) 2021-11-05 2022-11-04 Novel peptides

Publications (1)

Publication Number Publication Date
MX2024005508A true MX2024005508A (es) 2024-09-18

Family

ID=84329469

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005508A MX2024005508A (es) 2021-11-05 2022-11-04 Peptidos novedosos.

Country Status (9)

Country Link
US (3) US11873348B2 (https=)
EP (2) EP4426738A2 (https=)
JP (2) JP2024543043A (https=)
KR (2) KR20240114794A (https=)
AU (1) AU2022381977A1 (https=)
CA (1) CA3237463A1 (https=)
IL (1) IL312556A (https=)
MX (1) MX2024005508A (https=)
WO (2) WO2023079102A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240114794A (ko) * 2021-11-05 2024-07-24 엘리게이터 바이오사이언스 에이비 신규 펩티드
WO2024213533A1 (en) * 2023-04-13 2024-10-17 Alligator Bioscience Ab Combination therapies
CN117924468B (zh) * 2023-12-08 2024-09-20 南京大学 一种靶向登革热病毒ns1蛋白纳米抗体的制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
GB201115280D0 (en) * 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
WO2016172485A2 (en) * 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
US20190336615A1 (en) * 2017-01-27 2019-11-07 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
GB201820556D0 (en) 2018-12-17 2019-01-30 Alligator Bioscience Ab Novel polypeptides
CN113677703A (zh) * 2018-12-17 2021-11-19 鳄鱼生物科学公司 多肽
CN120383671A (zh) * 2019-09-30 2025-07-29 阿迪马布有限责任公司 被工程化用于优先轻链配对的ch1结构域变体和包括所述ch1结构域变体的多特异性抗体
KR20220103957A (ko) * 2019-10-23 2022-07-25 리브젠 바이오파마 홀딩스 리미티드 항-cd40 결합 분자 및 이를 포함하는 이중-특이적 항체
MX2022008524A (es) * 2020-01-09 2022-09-21 Biomunex Pharmaceuticals Anticuerpos multiespecificos que se unen tanto a linfocitos mait como a celulas tumorales.
KR20240114794A (ko) * 2021-11-05 2024-07-24 엘리게이터 바이오사이언스 에이비 신규 펩티드

Also Published As

Publication number Publication date
EP4426733A2 (en) 2024-09-11
US20240117074A1 (en) 2024-04-11
WO2023079102A3 (en) 2023-06-15
CA3237463A1 (en) 2023-05-11
US12448465B2 (en) 2025-10-21
US20260001961A1 (en) 2026-01-01
KR20240114794A (ko) 2024-07-24
JP2024542142A (ja) 2024-11-13
US20230312754A1 (en) 2023-10-05
WO2023079101A2 (en) 2023-05-11
WO2023079101A3 (en) 2023-06-15
WO2023079102A2 (en) 2023-05-11
JP2024543043A (ja) 2024-11-19
EP4426738A2 (en) 2024-09-11
KR20240099410A (ko) 2024-06-28
US11873348B2 (en) 2024-01-16
IL312556A (en) 2024-07-01
AU2022381977A1 (en) 2024-05-23

Similar Documents

Publication Publication Date Title
MX2024005508A (es) Peptidos novedosos.
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
MX2022003110A (es) Anticuerpos biespecificos contra ceacam5 y cd3.
MX2021015888A (es) Fusión de un anticuerpo que se une a cea y 4-1bbl.
AU2018449846A8 (en) An anti-B7-H3 antibody
PH12019502637A1 (en) Chimeric antigen receptors targeting flt3
WO2018187356A3 (en) Protein antigens and uses thereof
PH12019502275A1 (en) Anti-ilt4 antibodies and antigen-binding fragments
MX2022000652A (es) Anticuerpos contra claudina 18 y metodos de tratamiento del cancer.
MX2023001403A (es) Neoantigenos y metodos de su uso.
PH12022550195A1 (en) Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
SA519401494B1 (ar) مستقبلات مولد ضد كيمري لعلاج سرطان
MX2024015039A (es) Composiciones anti-cd24 y usos de las mismas
ZA201901557B (en) Bi specific anti¿muc16¿cd3 antibodies and anti¿muc16 drug conjugates
MY202919A (en) Novel bispecific polypeptide complexes
CR20200341A (es) Anticuerpos de unión a gprc5d
MY200602A (en) Antibodies against tim3 and uses thereof
EA201891966A1 (ru) Молекулы, связывающие bcma, и способы их применения
EP4273233A3 (en) Mr1 restricted t cell receptors for cancer immunotherapy
MX2019012606A (es) Celulas t que redirigen anticuerpos biespecificos para el tratamiento de canceres positivos a egfr.
MX2023011712A (es) Anticuerpos anti receptor de adhesion acoplado a proteinas g e2 (adgre2) y usos de los mismos.
JOP20210144A1 (ar) أجسام مضادة للبيريوستين واستخداماتها
MX2021011040A (es) Anticuerpos dirigidos contra c5ar.
MX2024002182A (es) Proteinas de union al factor de crecimiento transformante receptor beta ii (tgf-beta-rii).
MX2025015364A (es) Proteinas de union al antigeno contra el peptido antigenico b2 asociado al melanoma expresado en tumores (mageb2)